Scandinavian Medical Solutions (SMSMED) H1 24/25 earnings summary

Executive summary

• Revenue increased 20% year-over-year to DKK 122.7 million in H1 2024/25, but profitability declined due to margin pressure, higher costs, and geopolitical uncertainty.

• EBITDA dropped sharply to DKK 0.6 million from DKK 8.1 million in H1 2023/24, impacted by market conditions and U.S. investments.

• Net profit swung to a loss of DKK -2.3 million compared to a profit of DKK 2.6 million in the prior year period.

• Strategic investments in the U.S. subsidiary and adaptation to changing customer behavior led to lower sales margins and increased capacity costs.

• Focus for H2 is on strengthening cash flow, improving operational efficiency, and building resilience.

Financial highlights

• Revenue: DKK 122.7 million (H1 2024/25), up from DKK 102.6 million in H1 2023/24.

• Gross margin decreased from 25.9% to 19.7% year-over-year, mainly due to price adjustments in Equipment Solutions.

• EBITDA: DKK 0.6 million, down from DKK 8.1 million in H1 2023/24.

• Net loss: DKK -2.3 million, compared to net profit of DKK 2.6 million in H1 2023/24.

• Free cash flow before financing: DKK -20.7 million (H1 2023/24: DKK -14.6 million).

Outlook and guidance

• Revenue guidance for FY 2024/25 maintained at DKK 200–240 million; EBITDA guidance at DKK 11–15 million.

• Strategic focus on cost optimization, product mix adjustments, and risk management for H2 2024/25.

• Management expects cost-saving measures to take effect at the start of the next financial year.

• Emphasis on strengthening market share, cash flow improvement, and operational efficiency.